{"id":25539,"date":"2022-12-08T08:00:00","date_gmt":"2022-12-08T08:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-provides-update-on-phase-iii-contact-01-trial-evaluating-cabozantinib-in-combination-with-atezolizumab-in-patients-with-metastatic-non-small-cell-lung-cancer-previously-treated-with-immunotherap\/"},"modified":"2023-05-26T06:16:18","modified_gmt":"2023-05-26T06:16:18","slug":"ipsen-provides-update-on-phase-iii-contact-01-trial-evaluating-cabozantinib-in-combination-with-atezolizumab-in-patients-with-metastatic-non-small-cell-lung-cancer-previously-treated-with-immunotherap","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-provides-update-on-phase-iii-contact-01-trial-evaluating-cabozantinib-in-combination-with-atezolizumab-in-patients-with-metastatic-non-small-cell-lung-cancer-previously-treated-with-immunotherap\/","title":{"rendered":"Ipsen provides update on Phase III CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer previously treated with immunotherapy and chemotherapy"},"content":{"rendered":"\n